Curetis AG, a German medical diagnostics company, has expanded its Series A financing round by EUR 9.6 million with investment from additional leading life-science investors. Total capital raised in the round thus stands at EUR 34.1 million. The new investors include Forbion Capital Partners and Roche Venture Fund, while CD-Venture GmbH and members of the management team also participated.
A team from CMS Hasche Sigle led by lead partner Stefan-Ulrich Müller advised Curetis AG and the existing investors on all aspects of the transaction.
Curetis AG requires the funding to drive development of the company and of its diagnostic products through to the market stage. Founded in 2007, the company specialises in developing fast and reliable molecular tools for diagnosing serious bacterial infections (e.g. pneumonia) and more efficient identification of treatment options.
